Literature DB >> 7425244

Elective postoperative radiation therapy in stages III and IV epidermoid carcinoma of the head and neck.

B Vikram, E W Strong, J Shah, R H Spiro.   

Abstract

One hundred five patients with advanced (American Joint Committee stages III and IV) but resectable epidermoid carcinoma of the head and neck were treated with radical surgery and elective postoperative radiation therapy. Follow-up periods range from 16 to 66 months. Nineteen patients (18 percent) have had recurrence in the head and neck area. This is better than our past experience with surgical treatment alone in advanced head and neck cancer, in which 50 to 75 percent of patients had local recurrence within the 1st 18 months. When radiation therapy was started no later than 6 weeks after surgery, only 3 of 54 patients (5.5 percent) had local recurrence, but when there was a longer delay 16 of 51 patients (31.5 percent) had recurrence. These results suggest that elective postoperative radiation therapy improves local control in patients with advanced head and neck cancer, but that it should be delivered soon after surgery for maximum effectiveness.

Entities:  

Mesh:

Year:  1980        PMID: 7425244     DOI: 10.1016/0002-9610(80)90217-2

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  Management of intra-oral squamous cell carcinoma.

Authors:  A D McGregor
Journal:  J R Soc Med       Date:  1989-04       Impact factor: 5.344

Review 2.  Testing the Timing: Time Factor in Radiation Treatment for Head and Neck Cancers.

Authors:  Muhammad M Fareed; Rizwan Ishtiaq; Thomas J Galloway
Journal:  Curr Treat Options Oncol       Date:  2018-03-12

3.  Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation.

Authors:  G Los; f A Blommaert; R Barton; D D Heath; L den Engelse; C Hanchett; D Vicario; R Weisman; K T Robbins; S B Howell
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.